Stopping Biologics in IBD—What Is the Evidence?
Author:
Affiliation:
1. Department of Gastroenterology, CHU Liège University Hospital, Liège, Belgium
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,Immunology and Allergy
Link
http://academic.oup.com/ibdjournal/article-pdf/24/4/725/24655884/izx098.pdf
Reference57 articles.
1. Infliximab, azathioprine, or combination therapy for Crohn’s disease;Colombel;N Engl J Med,2010
2. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis;Panaccione;Gastroenterology,2014
3. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease;Walters;Gastroenterology,2014
4. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015
5. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease;Rutgeerts;Gastroenterology,1999
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Natural Products: A Dependable Source of Therapeutic Alternatives for Inflammatory Bowel Disease through Regulation of Tight Junctions;Molecules;2023-08-28
2. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab;Current Medical Research and Opinion;2023-08-26
3. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000;Scientific Reports;2023-08-21
4. Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study;Clinical Pharmacology & Therapeutics;2023-08-16
5. ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease;Journal of Crohn's and Colitis;2023-01-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3